Pharmaceutical

STAT+: Scott Gottlieb, Trump FDA chief, questions wheth...

One of the GOP's most prominent health care thinkers, former FDA Commissioner Sc...

More colonoscopy news and research

A study questioned colonoscopies as the gold standard of colon cancer screens. T...

Novovax’s Omicron-targeting Covid-19 vaccine obtains WH...

Novovax has been granted emergency use listing (EUL) by the World Health Organi...

Boehringer to leverage IBM’s technologies for antibody ...

Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s...

Abeona’s cell therapy secures priority approval date fo...

Abeona Therapeutics’s pz-cel (prademagene zamikeracel) has received a US Fo...

FDA accepts Orexo’s NDA for opioid overdose medication

The US Food and Drug Administration (FDA) has accepted Orexo’s new drug applica...

Radiopharmaceuticals reach record high with $408m in ve...

Venture financing for innovative radiopharmaceutical drugs witnessed an approxi...

FDA rejects Aldeyra’s dry eye drug, asks for more clini...

The US Food and Drug Administration (FDA) has issued a complete response letter...

Acelyrin claims errors by CRO Fortrea led to late-stage...

Immunology biotech Acelyrin has determined that its CRO partner Fortrea is resp...

Bayer’s stock drops to new 18-year low after asundexian...

Bayer’s stock price has plummeted to its lowest since 2005 after a clinical tri...

CTO Europe 2023: Cancer clinical trials shift as sector...

Building on the increased adoption of digital trial capabilities due to the Cov...

Emergent wins $75m BARDA contact for anthrax vaccine

Emergent BioSolutions has secured a $75m contract for the acquisition of the FD...

Opinion: The next Census could undercount the number of...

About 20 million disabled people may be erased if the U.S. Census Bureau moves f...

New research supports potential link between low-level ...

New research supports potential link between low-level lead exposure and liver i...

STAT+: With biotech in a slump, the industry’s job mark...

With biotech in a slump, the industry’s job market is feeling crimped.

STAT+: With new trial data, a blockbuster therapy from ...

The inflammation-targeting therapy Dupixent improved symptoms for patients with ...